Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript [Seeking Alpha]
Cue Biopharma, Inc. (CUE)
US:NASDAQ Investor Relations:
cuebiopharma.gcs-web.com/news-releases
Company Research
Source: Seeking Alpha
Company Participants Lucinda Warren - Interim CEO, Interim President,Principal Fin & Accounting Off., Chief Financial & Business Off. Daniel Baker - Interim Chief Development Officer Natasha Girgis Conference Call Participants Richard DiPaolo Jonathan Kay Presentation Operator Good morning, and welcome to the Cue Biopharma Virtual R&D Day. [Operator Instructions] Today's call will focus on a review of Cue Biopharma's lead asset, CUE-401 in development for the treatment of autoimmune and inflammatory diseases. Joining me on today's call is Cue Biopharma's Interim President and Chief Executive Officer, Lucinda Warren; Chief Development Officer, Dr. Daniel Baker; two recognized researchers in T regulatory cells and cytokines, Dr. Richard DiPaolo and Dr. Jonathan Kay, and other members of Cue's management team. Please note that this presentation and discussion is being recorded and will be available under the Events in the News and Publications section of the company'
Show less
Read more
Impact Snapshot
Event Time:
CUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CUE alerts
High impacting Cue Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
CUE
News
- Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026GlobeNewswire
- Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License AgreementGlobeNewswire
- Cue Biopharma Announces CEO Transition [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma Announces CEO Transition [TheStreet.com]TheStreet.com
- Cue Biopharma Announces CEO TransitionGlobeNewswire
CUE
Sec Filings
- 4/13/26 - Form 8-K
- 4/10/26 - Form 4
- 4/10/26 - Form 4
- CUE's page on the SEC website